Sawt Falasteen - GLP-1 Users Show Higher Rates of Nail Detachment in New Studies

Two recent small-scale studies presented at the 2026 Congress of the European Academy of Dermatology and Venereology (EADV) in Vienna have identified higher rates of hair and nail problems among users of GLP-1 medications. The findings raise questions about whether these physical changes are a direct consequence of rapid weight loss or an adverse effect of the drugs themselves.

The first study, a case-control analysis focused on nail health, compared 575 individuals using GLP-1 drugs with 1,329 people who had obesity or type 2 diabetes but had never taken the medication. The data showed that 39% of GLP-1 users reported nail detachment, known medically as onycholysis, compared to just 9% of the control group. Overall, 66% of users reported at least one nail disorder, versus 53% of controls. Nail discoloration was also more prevalent among users, affecting 46% compared to 17% in the control group.

Dr. Samantha Eisman, a dermatologist commenting on the findings, urged caution in interpreting the results. While the studies highlight a correlation between GLP-1 use and these physical symptoms, the exact mechanism remains unclear. The research contributes to an ongoing discussion regarding the side effect profile of these widely prescribed medications as their usage continues to expand globally.

W.Mansour--SF-PST